AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04240093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Abuse and Health Navigation Counseling
Description: 2 standard substance abuse and health navigation counseling
Study NCT04240093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medications for Opioid Use Disorder
Description: Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
Study NCT04240093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medications for Opioid Use Disorder
Description: Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
Study NCT00907296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT02306148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot and ankle strengthening
Description: Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
Study NCT04185792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NBSS, Qualiveen and SF-Qualiveen
Description: NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
Study NCT00907296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT05271825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broadband amplification from hearing aids
Description: Amplification from 125 Hz to 10 kHz
Study NCT05271825 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Band-limited amplification from hearing aids
Description: Amplification from 25 Hz to 3-4 kHz
Study NCT04292457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
Study NCT04292457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
Study NCT01278784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.05% Chitosan-N-Acetylcysteine eye drops
Description: Subjects will be randomized to receive one drop of the medical device in either the right or left eye
Study NCT01278784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.1% Chitosan-N-Acetylcysteine eye drops
Description: Subjects will be randomized to receive one drop of the medical device in either the right or left eye
Study NCT02067325 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thai massage
Study NCT02067325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai massage
Study NCT02292615 — intervention group
Intervention type: OTHER
Intervention: Medical Imaging
Study NCT02892721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training with feedback
Description: One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points.
Study NCT00803972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20
Study NCT00803972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Human Injection
Description: injection
Study NCT00803972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Injection
Description: injection
Study NCT04179513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 10mg
Description: 10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses.
Study NCT04179513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 20mg
Description: 20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses.
Study NCT01683058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: Aripiprazole IM Depot 400 mg or 300 mg
Study NCT04042272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)
Description: S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
Study NCT01403376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT01403376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-β-1
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study NCT01403376 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification
Study NCT01403376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification
Study NCT01878786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
Study NCT01897545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PV isolation
Description: The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
Study NCT01897545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation+renal denervation
Description: The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
Study NCT03329716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brace weaning
Description: For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
Study NCT00680758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients
Study NCT00680758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients
Study NCT00680758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: * Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients
Study NCT03311984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anti Xa level
Description: monitoring the anti-Xa level according to LMWH emploing
Study NCT03587753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fatty acid partitioning
Description: There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
Study NCT00769028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperimmune caprine serum
Description: Subcutaneous injection of serum, 1ml twice weekly for 6 months
Study NCT00769028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: Subcutaneous injection of albumin, 1ml twice weekly for 6 months
Study NCT00975065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)
Description: vildagliptin 50 mg bid plus metformin 1500mg
Study NCT00975065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin 1500mg plus metformin 500mg or 1000mg (Diabex)
Description: metformin 1500mg plus metformin 500mg or 1000mg
Study NCT02634021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine group
Description: intravenous loading of dexmedetomidine for 1 mcg/kg
Study NCT02634021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam group
Description: intravenous loading of midazolam for 0.1 mg/kg
Study NCT00582738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA-TAC (standard Treatment)
Description: Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
Study NCT00582738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Hepatitis C recurrence after orthotopic liver transplantation (OLT)
Study NCT02538133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 99mTc-Exametazime (HMPAO)-labeled leukocytes
Description: Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
Study NCT02300597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet based support and coaching
Description: Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
Study NCT00652899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
Study NCT00652899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
Study NCT00652899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: 25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
Study NCT00652899 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 200 cGy Day 1 preceding natural killer cell infusion.
Study NCT00652899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic natural killer cells
Description: Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
Study NCT00652899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 10 MU 3 times/week for a total of 6 doses beginning Day 0
Study NCT02706028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: underwater ultrasound
Description: underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
Study NCT02706028 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham underwater ultrasound
Description: ULTRON home OE-302® device is not turned on
Study NCT04478032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep transcranial magnetic stimulation with H7 coil
Description: low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
Study NCT04478032 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep transcranial magnetic stimulation with H7 coil
Description: low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
Study NCT02675413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Open-label
Study NCT00605670 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: patients will fill out two questionnaires post surgery
Study NCT00605670 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patient will fill out questionnaire before and 3 to 6 months after treatment.
Study NCT03443284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Partner
Description: Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
Study NCT03443284 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
Study NCT03984604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHI-921
Description: a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
Study NCT03984604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a vehicle oil will match CHI-921
Study NCT03642223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable iron isotopes
Description: Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
Study NCT03642223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable iron isotopes
Description: Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
Study NCT03605303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test/Control
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
Study NCT03605303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test/Control
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
Study NCT03605303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control/Test
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
Study NCT03605303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control/Test
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
Study NCT01973907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Sparing Resuscitation Strategy
Description: Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed.
Study NCT02153112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (15/15)
Description: Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Study NCT02153112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (15/50)
Description: Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Study NCT01167907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Description: 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
Study NCT01167907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
Study NCT01167907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
Study NCT02749383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.3%
Description: Topical application
Study NCT02749383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application
Study NCT02749383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study NCT00468936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: enteric coated Cellcept pills in applicable dose for patient
Study NCT00259298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Subcutaneous, 20 microgram (mcg)/day, 18 months